Almazov National Medical Research Centre, 197341 St-Petersburg, Russia.
First Pavlov State Medical University of Saint Petersburg, 197022 St. Petersburg, Russia.
Int J Mol Sci. 2021 Jan 24;22(3):1149. doi: 10.3390/ijms22031149.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and life-threatening complication of pulmonary embolism. As existing animal models of CTEPH do not fully recapitulate complex disease pathophysiology, we report a new rat model for CTEPH evoked by repetitive embolization of the distal pulmonary artery branches with partially biodegradable alginate microspheres (MSs). MSs (180 ± 28 μm) were intravenously administered eight times at 4-day intervals; control animals received saline. The validity of the model was confirmed using transthoracic echocardiography, exercise testing, catheterization of the right ventricle, and histological examination of the lung and heart. The animals in the CTEPH group demonstrated a stable increase in right ventricular systolic pressure (RVSP) and decreased exercise tolerance. Histopathological examination revealed advanced medial hypertrophy in the small pulmonary arteries associated with fibrosis. The diameter of the main pulmonary artery was significantly larger in the CTEPH group than in the control group. Marinobufagenin and endothelin-1 serum levels were significantly elevated in rats with CTEPH. In conclusion, repetitive administration of alginate MSs in rats resulted in CTEPH development characterized by specific lung vasculature remodeling, reduced exercise tolerance, and a persistent rise in RVSP. The developed model can be used for pre-clinical testing of promising drug candidates.
慢性血栓栓塞性肺动脉高压(CTEPH)是肺栓塞的一种罕见且危及生命的并发症。由于现有的 CTEPH 动物模型不能完全重现复杂的疾病病理生理学,我们报告了一种新的大鼠模型,该模型通过用部分可生物降解的藻酸盐微球(MS)重复栓塞肺小动脉分支来诱发 CTEPH。MS(180±28μm)以 4 天间隔静脉注射 8 次;对照动物接受生理盐水。通过经胸超声心动图、运动试验、右心室导管插入术和肺及心脏的组织学检查证实了该模型的有效性。CTEPH 组的动物表现出右心室收缩压(RVSP)稳定升高和运动耐量降低。组织病理学检查显示小肺动脉中晚期的中膜肥厚与纤维化有关。CTEPH 组的主肺动脉直径明显大于对照组。Marinobufagenin 和内皮素-1 的血清水平在 CTEPH 大鼠中显著升高。总之,在大鼠中重复给予藻酸盐 MS 可导致 CTEPH 的发展,其特征为特定的肺血管重塑、运动耐量降低和 RVSP 持续升高。所开发的模型可用于有前途的药物候选物的临床前测试。